Swedish pharmaceutical and medtech centre to boost R&D (research and development):
This article was originally published in Clinica
A new centre established at the University of Lund, and the first of its kind in Sweden, is set to promote research into medical devices and pharmaceuticals. Known as the "medicines centre", its aim is to make research more transparent and to increase the cross-disciplinary exchange of information in fields such as molecular biology and cell biology. It is hoped that the centre will develop new technologies and methods that will be of direct interest to both national and international industry. The centre will not be concerned with legal or patent matters with respect to its research, as this will be handled by Lund University's innovations unit, which was set up in 2003. Instead, it will urge more co-operations between researchers, industry and research financing bodies.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.